Details
Stereochemistry | RACEMIC |
Molecular Formula | C3H6O3 |
Molecular Weight | 90.0779 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(O)C(O)=O
InChI
InChIKey=JVTAAEKCZFNVCJ-UHFFFAOYSA-N
InChI=1S/C3H6O3/c1-2(4)3(5)6/h2,4H,1H3,(H,5,6)
DescriptionSources: http://labeling.pfizer.com/ShowLabeling.aspx?id=4617Curator's Comment: Description was created based on several sources, including
https://www.brambleberry.com/sodium-lactate-p5127.aspx | http://www.fbcindustries.com/Sodium_Lactate.aspx
Sources: http://labeling.pfizer.com/ShowLabeling.aspx?id=4617
Curator's Comment: Description was created based on several sources, including
https://www.brambleberry.com/sodium-lactate-p5127.aspx | http://www.fbcindustries.com/Sodium_Lactate.aspx
Sodium lactate is primarily indicated as a source of bicarbonate for prevention or control of mild to moderate metabolic acidosis in patients
with restricted oral intake whose oxidative processes are not seriously impaired. Sodium Lactate is most commonly associated with an E number of “E325” Sodium Lactate blends are commonly used in meat and poultry products to extend shelf life and increase food safety. They have a broad antimicrobial action and are effective at inhibiting most spoilage and pathogenic bacteria. In addition sodium lactate is used in cosmetics as a humectant, providing moisture.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: WP408 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10904049 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | SODIUM LACTATE IN PLASTIC CONTAINER Approved UseSodium Lactate Injection, USP 50 mEq (5 mEq/mL), is primarily indicated, after dilution, as a source of bicarbonate for prevention or control of mild to moderate metabolic acidosis in patients with restricted oral intake whose oxidative processes are not seriously impaired. It is not intended nor effective for correcting severe acidotic states which require immediate restoration of plasma bicarbonate levels. Sodium lactate has no advantage over sodium bicarbonate and may be detrimental in the management of lactic acidosis Launch Date1984 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
20.2 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15236001/ |
39.76 mmol other, intravenous dose: 39.76 mmol route of administration: Intravenous experiment type: OTHER co-administered: |
LACTATE ION, L- plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
2.03 mg/dL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15236001/ |
39.76 mmol other, intravenous dose: 39.76 mmol route of administration: Intravenous experiment type: OTHER co-administered: |
LACTIC ACID, D- plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
53.35 mg × h/dL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15236001/ |
39.76 mmol other, intravenous dose: 39.76 mmol route of administration: Intravenous experiment type: OTHER co-administered: |
LACTATE ION, L- plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
4.44 mg × h/dL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15236001/ |
39.76 mmol other, intravenous dose: 39.76 mmol route of administration: Intravenous experiment type: OTHER co-administered: |
LACTIC ACID, D- plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Sample Use Guides
In Vivo Use Guide
Sources: http://labeling.pfizer.com/ShowLabeling.aspx?id=4617
Sodium Lactate Injection, USP 50 mEq (5 mEq/mL) is administered intravenously only after addition to a larger volume of fluid. The amount of sodium ion and lactate ion to be added to larger volume intravenous fluids should be determined in accordance with the electrolyte requirements of
each individual patient. All or part of the content(s) of one (50 mEq in 10 mL) or more vial containers may be added to other intravenous solutions to provide any desired number of milliequivalents of lactate anion (with the same number of milliequivalents of Na+ ). The contents of one container (50 mEq in 10 mL) added to 290 mL of a nonelectrolyte solution or of sterile water for injection will provide 300 mL of an approximately isotonic (1/6 molar) concentration of sodium lactate (1.9%), containing 167 mEq/liter each of Na+ and lactate anion
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26181372
10 mM sodium lactate inhibits activated T cell motility
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
CODEX ALIMENTARIUS (GSFA) |
INS-270
Created by
admin on Fri Dec 15 15:14:55 GMT 2023 , Edited by admin on Fri Dec 15 15:14:55 GMT 2023
|
||
|
JECFA EVALUATION |
INS-270
Created by
admin on Fri Dec 15 15:14:55 GMT 2023 , Edited by admin on Fri Dec 15 15:14:55 GMT 2023
|
||
|
CFR |
21 CFR 862.1450
Created by
admin on Fri Dec 15 15:14:55 GMT 2023 , Edited by admin on Fri Dec 15 15:14:55 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
367919
Created by
admin on Fri Dec 15 15:14:55 GMT 2023 , Edited by admin on Fri Dec 15 15:14:55 GMT 2023
|
PRIMARY | |||
|
1314409
Created by
admin on Fri Dec 15 15:14:55 GMT 2023 , Edited by admin on Fri Dec 15 15:14:55 GMT 2023
|
PRIMARY | RxNorm | ||
|
3B8D35Y7S4
Created by
admin on Fri Dec 15 15:14:55 GMT 2023 , Edited by admin on Fri Dec 15 15:14:55 GMT 2023
|
PRIMARY | |||
|
100000089031
Created by
admin on Fri Dec 15 15:14:55 GMT 2023 , Edited by admin on Fri Dec 15 15:14:55 GMT 2023
|
PRIMARY | |||
|
LACTIC ACID, DL-
Created by
admin on Fri Dec 15 15:14:55 GMT 2023 , Edited by admin on Fri Dec 15 15:14:55 GMT 2023
|
PRIMARY | Description: A colourless or slightly yellow, clear, syrupy, caustic liquid; odourless or with a slight characteristic odour. Miscibility: Miscible with water, ethanol (~750 g/l) TS, and ether R.Category: Used in the preparation of sodium lactate solution as electrolyte. Storage: Lactic acid should be kept in a tightly closed container.Additional information. Lactic acid as described is not suitable for parenteral administration (haemodialysis). Lactic acid is usuallya racemate (RS), but the (+)-(S)-isomer may predominate; it is hygroscopic. Requirement: Definition- Lactic acid is a mixture of lactic acid, its condensation products, and water, the equilibrium between the components being dependent on the concentration and temperature. Lactic acid contains not less than 88.0% m/mand not more than the equivalent of 92.0% m/mof C3H6O3. | ||
|
50-21-5
Created by
admin on Fri Dec 15 15:14:55 GMT 2023 , Edited by admin on Fri Dec 15 15:14:55 GMT 2023
|
PRIMARY | |||
|
598-82-3
Created by
admin on Fri Dec 15 15:14:55 GMT 2023 , Edited by admin on Fri Dec 15 15:14:55 GMT 2023
|
SUPERSEDED | |||
|
3B8D35Y7S4
Created by
admin on Fri Dec 15 15:14:55 GMT 2023 , Edited by admin on Fri Dec 15 15:14:55 GMT 2023
|
PRIMARY | |||
|
209-954-4
Created by
admin on Fri Dec 15 15:14:55 GMT 2023 , Edited by admin on Fri Dec 15 15:14:55 GMT 2023
|
PRIMARY | |||
|
849585-22-4
Created by
admin on Fri Dec 15 15:14:55 GMT 2023 , Edited by admin on Fri Dec 15 15:14:55 GMT 2023
|
SUPERSEDED | |||
|
C80130
Created by
admin on Fri Dec 15 15:14:55 GMT 2023 , Edited by admin on Fri Dec 15 15:14:55 GMT 2023
|
PRIMARY | |||
|
C45678
Created by
admin on Fri Dec 15 15:14:55 GMT 2023 , Edited by admin on Fri Dec 15 15:14:55 GMT 2023
|
CONCEPT | Industrial Aid | ||
|
DTXSID7023192
Created by
admin on Fri Dec 15 15:14:55 GMT 2023 , Edited by admin on Fri Dec 15 15:14:55 GMT 2023
|
PRIMARY | |||
|
800
Created by
admin on Fri Dec 15 15:14:55 GMT 2023 , Edited by admin on Fri Dec 15 15:14:55 GMT 2023
|
PRIMARY | |||
|
612
Created by
admin on Fri Dec 15 15:14:55 GMT 2023 , Edited by admin on Fri Dec 15 15:14:55 GMT 2023
|
PRIMARY | |||
|
152-36-3
Created by
admin on Fri Dec 15 15:14:55 GMT 2023 , Edited by admin on Fri Dec 15 15:14:55 GMT 2023
|
SUPERSEDED | |||
|
200-018-0
Created by
admin on Fri Dec 15 15:14:55 GMT 2023 , Edited by admin on Fri Dec 15 15:14:55 GMT 2023
|
NON-SPECIFIC STEREOCHEMISTRY | |||
|
m6654
Created by
admin on Fri Dec 15 15:14:55 GMT 2023 , Edited by admin on Fri Dec 15 15:14:55 GMT 2023
|
PRIMARY | Merck Index | ||
|
SUB22126
Created by
admin on Fri Dec 15 15:14:55 GMT 2023 , Edited by admin on Fri Dec 15 15:14:55 GMT 2023
|
PRIMARY | |||
|
1334714-39-4
Created by
admin on Fri Dec 15 15:14:55 GMT 2023 , Edited by admin on Fri Dec 15 15:14:55 GMT 2023
|
SUPERSEDED | |||
|
DB04398
Created by
admin on Fri Dec 15 15:14:55 GMT 2023 , Edited by admin on Fri Dec 15 15:14:55 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)